TW200819446A - Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor - Google Patents

Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor Download PDF

Info

Publication number
TW200819446A
TW200819446A TW096130026A TW96130026A TW200819446A TW 200819446 A TW200819446 A TW 200819446A TW 096130026 A TW096130026 A TW 096130026A TW 96130026 A TW96130026 A TW 96130026A TW 200819446 A TW200819446 A TW 200819446A
Authority
TW
Taiwan
Prior art keywords
compound
formula
salt
crystalline
salt form
Prior art date
Application number
TW096130026A
Other languages
English (en)
Chinese (zh)
Inventor
Xiao-Ming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vincenzo Liotta
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200819446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200819446A publication Critical patent/TW200819446A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096130026A 2006-08-14 2007-08-14 Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor TW200819446A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
TW200819446A true TW200819446A (en) 2008-05-01

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096130026A TW200819446A (en) 2006-08-14 2007-08-14 Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor

Country Status (11)

Country Link
US (1) US7956189B2 (enExample)
EP (1) EP2069337A1 (enExample)
JP (3) JP2010500406A (enExample)
CN (1) CN101522671A (enExample)
AR (1) AR062373A1 (enExample)
CA (1) CA2660703A1 (enExample)
CL (1) CL2007002366A1 (enExample)
MX (1) MX2009001770A (enExample)
PE (1) PE20080424A1 (enExample)
TW (1) TW200819446A (enExample)
WO (1) WO2008021271A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2419610C2 (ru) 2005-05-26 2011-05-27 Ньюрон Системз, Инк. Композиции и способы лечения заболевания сетчатки
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
US9687481B2 (en) 2013-01-23 2017-06-27 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907354B1 (ko) 2004-05-18 2009-07-10 쉐링 코포레이션 Pde4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸

Also Published As

Publication number Publication date
JP2010500406A (ja) 2010-01-07
EP2069337A1 (en) 2009-06-17
JP2013032394A (ja) 2013-02-14
PE20080424A1 (es) 2008-04-28
US7956189B2 (en) 2011-06-07
MX2009001770A (es) 2009-02-25
CN101522671A (zh) 2009-09-02
AR062373A1 (es) 2008-11-05
CA2660703A1 (en) 2008-02-21
CL2007002366A1 (es) 2008-03-14
WO2008021271A1 (en) 2008-02-21
JP2012176989A (ja) 2012-09-13
US20080108818A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
TW200819446A (en) Maleate, tosylate, fumarate, and oxalate salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide and preparation process therefor
AU2023202085B2 (en) Polymorphic forms of RAD1901-2HCL
CN105143194B (zh) 依洛昔巴特的结晶修饰物
TWI379681B (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US9610278B2 (en) Glycopyrrolate salts
CN107873029B (zh) 依鲁替尼与羧酸的共晶体
TW202019914A (zh) 2-(3,5-二氯-4-((5-異丙基-6-側氧基-1,6-二氫噠嗪-3-基)氧)苯基)-3,5-二側氧基-2,3,4,5-四氫-1,2,4-三嗪-6-腈之固體型式
US11291651B2 (en) Glycopyrrolate salts
BR122018014454B1 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
JP6691218B2 (ja) 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
JP2013533298A (ja) 4−[−2−[[5−メチル−1−(2−ナフタレニル)−1h−ピラゾール−3−イル]オキシ]エチル]モルホリン塩酸塩の固体形態
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
TW202434233A (zh) 化合物a的鹽和晶型、其製備方法和用途
JP2019518058A (ja) スピロ−オキシインドール化合物の固体状態形
EA036295B1 (ru) Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
JP7152122B2 (ja) エダラボン塩
TW201143761A (en) Tablet formulation of ezatiostat
TW202033508A (zh) 貝前列素-314d晶體及其製備方法
TW201018660A (en) Chemical process
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
JP2025510061A (ja) 縮合三環式誘導体又はその薬学的に許容される塩の結晶
CN115246830A (zh) 一种酸的固体形式及其制备方法
TW202502340A (zh) 菸酸酯類化合物的無定型物、多晶型物及其製備方法和用途
WO2025180349A1 (zh) 化合物的固体及其制备方法和用途